Royalty Report: Medical, Supply, Wound Care – Collection: 279379

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Medical
  • Supply
  • Wound Care
  • Surgical
  • Device
  • Packaging & Containers
  • Therapeutic
  • Regenerative medicine
  • Disease
  • Orthopedic
  • Tissue

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279379

License Grant
Licensor shall grant to Licensee and Affiliates under CyroSeal II Intellectual Property, and for the life of such CyroSeal II Intellectual Property, a non-exclusive, royalty bearing, license to make, use, offer to sell, sell, and import Products throughout the Territory for use in the Field of Use. Licensee shall have the right to grant sublicenses to others under the CyroSeal II Intellectual Property to import, distribute, offer to sell, sell, and obtain regulatory clearances for Products.
License Property
Product(s) means a fibrinogen concentration kit containing Licensor’s CryoSeal II Kit (minus Fibrinogen Reagent) and Licensee’s Plasma Fractioning Tube, ACD-A anti-coagulant, labeling per Licensee’s direction, and instructions.

CryoSeal II Kit is known as a product which harvests a fibrinogen rich solution of adhesive & clotting proteins.

CryoSeal II Kit means Licensor’s fibrinogen plus disposable, labeling as specified by Licensee, and applicators contained in a sterile package.

CyroSeal II Intellectual Property means Licensors Intellectual Property required to make, use, offer for sell, sell, and import the Product.

Field of Use
This agreement pertains to the drug industry relating to products that process autologous human cells, such as contained in blood, to product therapeutic products.   Field of Use means surgical hemostats, graft delivery systems, and surgeries.

The product will feature a fibrinogen harvesting disposable in combination with Licensee's Clotalyst(TM) System that can produce fibrin sealant from a patient's own blood in less than 30 minutes. Fibrin sealant is an adhesive gel used by surgeons to stop bleeding and bond tissue.

Licensee plans to combine Licensor's protein harvesting technology with its currently offered and future autologous therapies to manufacture autologous fibrin sealant in a peri-operative setting.

The product will feature a fibrinogen harvesting disposable in combination with Licensee's Clotalyst(TM) System that can produce fibrin sealant from a patient's own blood in less than 30 minutes. Fibrin sealant is an adhesive gel used by surgeons to stop bleeding and bond tissue.

IPSCIO Record ID: 28309

License Grant
Canadian Licensor hereby grants Swiss Licensee, a 19.2% shareholder, a sole and exclusive worldwide license to manufacture the Initial Product under the Patent Rights and Licensor Technology.
License Property
'Initial Products' shall mean the fibrin sealant product known under the trade name Hemaseel HMN.

Hemaseel HMN is a fibrin sealant produced using Licensor's proprietary fibrin sealant technology. Hemaseel HMN is comprised of fibrinogen and thrombin, without bovine-derived aprotinin.

The production of the fibrinogen and thrombin components of Hemaseel HMN involves their isolation and purification from human-sourced plasma.

Field of Use
Hemaseel is used in surgeries involving cardiopulmonary bypass, spleen repair surgery, and colostomy closures.

IPSCIO Record ID: 1957

License Grant
The Company entered into an exclusive manufacturing and distribution agreement with Japanese company for the territory of Japan for the CryoSeal System.
License Property
The CryoSeal System is a small, floor-standing thermodynamic device and special blood processing container which harvests Cryo from a donor's blood plasma; an automated rapid method of preparing cyroprecipitated AHF (Cryo) –a biological product licensed (approved) by the FDA for intravenous treatment of hemophilia; the Autologous Tissue Sealant System comprises Thermogenesis' thermodynamic device for controlling plasma temperature, a sterile plasma collection-and-harvesting bag and disposable applicators.  The system allows the rapid harvesting of cryoprecipitate – or concentrated clotting proteins, including fibrinogen – that can be used by surgeons to control bleeding and seal tissues during surgery.

United States, Serial No. 07789293 – Device for Fractionating Constituent Components of a Substance using Cryoprecipitation and Serial No. 08005989 — Fibrinogen Processing  Apparatus Method and Container, covering said inventions (The Patent Applications) and is preparing additional patent application, all of which either have been and/or will be filed in Japan.

Field of Use
The rights granted apply for intravenous treatment of hemophilia and relating to the design and manufacture of a freezing and thawing System for the rapid harvesting of cryoprecipitate from human plasma.

IPSCIO Record ID: 203253

License Grant
Licensor appoints the Japanese Licensee as Licensor’s exclusive distributor within the Territory and Asian Pacific Rim Countries to market, distribute and sell the Product, including TAD Stand Alone, to be supplied by Licensor for any purpose, including, but not limited to, surgical procedures and regeneration medical treatment.

Licensor grants the exclusive right and license, with the right to sublicense for marketing and manufacturing purposes only, to use all trademarks with respect to the Product owned by Licensor in connection with the manufacturing, marketing, distribution, sale and post-sale field service, technical assistance and support of its rights hereunder in the Territory and Asian Pacific Rim Countries.

License Property
The product line is for innovative products and services that process and store adult stem cells, including the CryoSeal Fibrin Sealant System wound care product line.

The CryoSeal Fibrin Sealant (FS) System is a medical device that simultaneously produces cryoprecipitate and thrombin from a unit of autologous plasma. When components are mixed they form a fibrin sealant for use in liver resection surgery as an adjunct to hemostasis.  CryoSeal Fibrin Sealant System wound care product line allows the production of fibrin sealant from a single unit of human plasma.

Field of Use
The CryoSeal FS System is intended for the preparation of fibrin sealant from a unit of autologous plasma in a closed, sterile fluid path. The autologous fibrin sealant is indicated for use as an adjunct to hemostasis on the incised liver surface in patients undergoing liver resection when control of bleeding by standard surgical techniques is ineffective or impractical.

IPSCIO Record ID: 5518

License Grant
The licensee, a Canadian corporation, was granted a perpetual license to make, use, sell, develop and import all assets relating to the fibrin sealant product.  

There was an improvement–a frozen formulation named Hemaseel APR (FF).  A binding letter of understanding was executed relative to this product in 1999.

License Property
The assets included eight patents, trade secrets, know how, clinical data, production information, quality assurance data and FDA-related information.  

The product is a surgical sealant and is a frozen version of Hemaseel APR.  It is a hemostatic agent capable of arresting bleeding, with the mechanical strength to attach tissues together and to last through the first phase of the body's healing process.  It contains two human blood components fibrinogen and thrombin, which form the essential part of a blood clot, and a third component, aprotinin, which acts as an anti-fibrinolytic agent.  Application for approval was submitted to the FDA in 2002 and approval is expected in 2004.

IPSCIO Record ID: 5517

License Grant
Licensor of Switzerland hereby grants and agrees to grant to Licensee of Canada, its successors and assigns, a perpetual, worldwide, transferable exclusive license under all Licensor Technology to make, have made, use, sell or otherwise develop or commercialize fibrin sealants or any of the components thereof, including but not limited to, the right to make, have made, use, sell or otherwise develop or commercialize the Products and/or Devices and the right to establish facilities for manufacturing and otherwise commercializing the Products and/or Devices.
License Property
Products shall mean any product consisting of one or both of two components (a) Fibrinogen (and all associated proteins, including Factor XIII and Fibronectin), whether in liquid or lyophilized form, isolated by repeated salt precipitation in the presence of amino-6-hexanoic acid, the latter being used to prevent co-precipation of plasminogen (b) Thrombin, whether in liquid or lyophilized form, with any associated components, as isolated by ion-exchange chromatography over a sulpho-alkyl group – containing gel, weight elution of the protein by acetate buffer.

Device means any accessory, applicator, device or other means for reconstitution and/or application of the Products, but specifically excluding the bandage falling within the scope of patents applied for or granted to the American Red Cross.

Clinical trials are just being considered. FDA approval is anticipated for 2006. Licensor is wholly owned by Australian corporation.

Field of Use
The Canadian licensee acquired all the technology as well as certain specialized manufacturing equipment to produce Hemaseel HMN fibrin sealant (a surgical sealant).    The fibrin sealant is an all-human product for use in certain applications, ie. Neurosurgery. The Hemaseel HMN process uses epsilon-amino-caproic acid (EACA) during the manufacturing process to eliminate undesirable plasminogen from the sealant.  The use of EACA, instead of tranexamic acid or aprotinin, differentiates this sealant from other fractiation methods by providing better purity, production yields, and an enhanced viral safety profile.  The tissue sealant is extracted from human plasma.  The product will be delivered in a kit format, with lyophilized clotting protein concentrates in vials, and ancillaries (syringes, needles).

IPSCIO Record ID: 253984

License Grant
Licensor grants
—  an exclusive license under the Licensed Technology, CoStasis Ingredient Improvements and CoStasis Ingredient Improvement Patents to make, have made, sell, have sold, offer for sale, export, have exported, import and have imported CoStasis Products in the Orthopedic Hemostat Field in the Territory;

—  until such time as Licensor elects to distribute, promote, market and/or sell one or more Licensor Branded CoStasis Products, an exclusive license under the Licensed Technology, CoStasis Ingredient Improvements and CoStasis Ingredient improvement Patents to make, have made, sell, have sold, offer for sale, export, have exported, import and have imported CoStasis Products in the Non-Orthopedic Hemostat Field in the Territory,

—  from and after such time as Licensor elects to distribute, promote, market and/or sell one or more Licensor Branded CoStasis Products, a coexclusive, meaning that only the Parties can act in each country of the Territory, license under the Licensed Technology, CoStasis Ingredient Improvements and CoStasis Ingredient Improvement Patents to make, have made, sell, have sold, offer for sale, export, have exported, import and have imported CoStasis Products in the Non-Orthopedic Hemostat Field in the Territory;

—  a non-exclusive license under the Licensed Technology to make, have made, use, sell, have sold, offer for sale, export, have exported, import and have imported CellPaker Products and Accessories in the CellPaker Field in the Territory; and

—  a non-exclusjve license under the Licensed Technology and CoStasis Ingredient improvements and CoStasis Ingredient Improvement Patents to use, including, without limitation, to research, have researched, develop and have developed) CoStasis Ingredients and Formulated CoStasis Ingredients, but only for uses directly related to Licensees Product licenses and rights hereunder, Products, other than Licensor Branded CoStasis Products, and Accessories in the Licensed Field in the Territory.

License Property
CoStasis Ingredients means collagen and thrombin.

CoStasis® Surgical Hemostat product is a sterile suspension of bovine collagen and bovine thrombin in calcium chloride.

CoStasis Product means a product containing the Formulated CoStasis Ingredients in a syringe.

CellPaker® Plasma Collection Svstem is a needleless syringe device for drawing blood from a human for direct placement into a centrifuge for centrifuging to separate plasma from red and white blood cells.

CellPaker Product means a CellPaker® Plasma Collection System product for use with CoStasis Products, CoStasis Ingredients' means collagen and thrombin.

Field of Use
Licensed Field means, collectively or individually, as the context requires,
(a) the Orthopedic Hemostat Field;
(b) the Non-Orthopedic Hemostat Field; and
(c) the CellPaker Field.

The terms Licensed Field, Orthopedic Hemostat Field and Non-Orthopedic Hemostat Field are expressly inapplicable to Drug-Loaded Products, even if a Drug-Loaded Product is approved for human use in the Licensed Field.

CellPaker Field means human medical uses of the CellPaker Products and/or Accessories in connection with CoStasis Products.

Non-Orthopedic Hemostat Field means, with respect to a CoStasis Product, human medical uses of the CoStasis Product as a Hemostat for all indications, other than indications within the Orthopedic Hemostat Field.

Orthopedic Hemostat Field means, with respect to a CoStasis Product, human medical uses of the CoStasis Product as a Hemostat for all indications treated by an orthopedic surgeon or other surgeon relating to the surgical repair of diseases or injuries of the spine, bone or related soft tissue, such as ligaments or cartilage.

IPSCIO Record ID: 26682

License Grant
Licensor hereby grants to Licensee for the a non-exclusive, royalty-bearing license to manufacture, have made, use, import, sell, promote, market, offer for sale, or otherwise transfer Platelet Products, Activated Platelet Gel Services and Experimental Platelet Gel Therapies for use in practicing or involving the practice of processes covered by one or more claims of the Licensed Patent in any field of use.
License Property
The controversy between the Parties based upon Licensee's manufacture, use, marketing, offer to sell, and/or sale of products alleged to infringe U.S. Patent No. 5,165,938.

Activated Platelet Gel Therapies are defined as methods of treating damaged tissues and/or wounds using topical compositions containing platelets activated by adding thrombin or another biologic release agent, or containing substances released from platelets after activation by adding thrombin or another biologic release agent.

Experimental Platelet Gel Therapies are defined as methods of treating damaged tissues and/or wounds using topical compositions containing platelets activated by locally present thrombin or another biologic release agent, or containing substances released from platelets after activation by locally present thrombin or another biologic release agent, i.e., without adding thrombin or another biologic release agent.

Schedule of SafeBlood Branded Single Use Disposable Kit Products
Item Description

Manufacturer Number

SafeBlood Graft Kit
                    
SBG KitSB101 / W

SafeBlood Graft Kit

SBG KitSB101 / W 1

SafeBlood Graft Kit

SBG KitSB102 / W

SafeBlood Graft Kit

SBG KitSB201 / W

SafeBlood Graft Kit

SBG Kit SB 103

SafeBlood Graft Kit 800-1001A(1)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(2)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(3)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(4)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(5)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(6)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A(7)

BIOMETGPS 800-1001A

SafeBlood Graft Kit 800-1001A

BIOMETGPS 800-1001A

GPS Counter Balance

BIOMETGPS 800-0508

Schedule of SafeBlood Branded Single Use Disposable Component Products

Item Description

Manufacturer Number

SBG Graft Activator
    
CD SBG-1005

Ratio Procedure kit

Micromedics SA-4400

Blending Connector

Micromedics SA-3674

Single Spray Tip

Micromedics SA-3671

Dual Spray Applicator Tip

Micromedics SA-3660

Dual Tip

Micromedics SA-0205

Schedule of SafeBlood Branded Capital Equipment Products
Item Description

Manufacturer Number

GPS Centrifuge 120 Volt 50-60HZ
    
GPS – 7426

IPSCIO Record ID: 332218

License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts
(a) an exclusive license under the Licensed Technology, CoStasis Ingredient Improvements and CoStasis Ingredient Improvement Patents to make, have made, sell, have sold, offer for sale, export, have exported, import and have imported CoStasis Products in the Orthopedic Hemostat Field in the Territory;
(b) until such time as Licensor elects to distribute, promote, market and/or sell one or more Licensor-Branded CoStasis Products, an exclusive license under the Licensed Technology, CoStasis Ingredient Improvements and CoStasis Ingredient Improvement Patents to make, have made, sell, have sold, offer for sale, export, have exported, import and have imported CoStasis Products in the Non-Orthopedic Hemostat Field in the Territory;
(c) from and after such time as Licensor elects to distribute, promote, market and/or sell one or more Licensor-Branded CoStasis Products, a co-exclusive (meaning that only Licensee and Licensor can act in each country of the Territory) license under the Licensed Technology, CoStasis Ingredient Improvements and CoStasis Ingredient Improvement Patents to make, have made, sell, have sold, offer for sale, export, have exported, import and have imported CoStasis Products in the Non-Orthopedic Hemostat Field in the Territory;
(d) a non-exclusive license under the Licensed Technology to make, have made, use, sell, have sold, offer for sale, export, have exported, import and have imported CellPaker Products and Accessories in the CellPaker Field in the Territory; and
(e) a non-exclusive license under the Licensed Technology and CoStasis Ingredient Improvements and CoStasis Ingredient Improvement Patents to use (including, without limitation, to research, have researched, develop and have developed) CoStasis Ingredients and Formulated CoStasis Ingredients (but only for uses directly related to Licensee’s Product licenses and rights hereunder), Products (other than Licensor-Branded CoStasis Products) and Accessories in the Licensed Field in the Territory.

Solely for purposes of fulfilling Licensee’s obligations under this Agreement with respect to the Licensor Trademarks ANGIOTECHKNOWLEDGY® and CELLPAKER® (or other Licensor Trademark(s) that Licensor may wish to substitute therefor during the Term), Licensor grants to Licensee a non-exclusive right and license to use such Licensor Trademarks for this limited purpose.

License Property
Products means CoStasis Products and CellPaker Products, collectively or individually, as the context requires.

CoStasis Product(s) means a product(s) containing the Formulated CoStasis Ingredients in a syringe that is manufactured by or for Licensee or by or for Licensor (and/or Licensor’s Affiliates) for use and exploitation in the Licensed Field in accordance with this Agreement. The current formulation of the CoStasis Product is described in Exhibit A hereto. The term “CoStasis Products” includes Licensor-Branded CoStasis Products. The term CoStasis Products shall expressly exclude Drug-Loaded Products. However, Licensee may add one or more additional ingredients to the CoStasis Ingredients to make a CoStasis Product; provided that no such additional ingredient is an active pharmaceutical ingredient or a drug.
Description A sterile suspension of bovine collagen and bovine thrombin in calcium chloride.

CoStasis Ingredients means collagen and thrombin.

Licensor-Branded CoStasis Product(s) means a CoStasis Product(s) for use and exploitation in the Non-Orthopedic Hemostat Field that is distributed, promoted, marketed and/or sold by or on behalf of Licensor and/or its Affiliates under one or more Licensor Trademarks selected by Licensor; provided that if Licensee loses its exclusive (or co-exclusive, as applicable) rights with respect to CoStasis Products in the Orthopedic Hemostat Field, then the term Licensor-Branded CoStasis Product(s) shall also include use and exploitation in the Orthopedic Hemostat Field.

CellPaker Product(s) means a CellPaker® Plasma Collection System product(s) for use with CoStasis Products, as  described hereto.
Description A needle-less syringe device for drawing blood from a human for direct placement into a centrifuge for centrifuging to separate plasma from red and white blood cells.
“Licensed Patents” means
5,290,552 – Surgical adhesive material
6,096,309 – Compositions containing thrombin and microfibrillar nanometer collagen, and methods for preparation and use thereof
5,968,018 – Cell separation device and in-line orifice mixer system

LicensorTrademark(s) means a Trademark(s) owned or Controlled by Licensor. Licensor shall select one or more Licensor Trademarks for use in conjunction with an Licensor-Branded CoStasis Product(s), and these Licensor Trademark(s) shall be different from Licensee Trademark(s) used in conjunction with CoStasis Product(s). Licensor Trademark(s) shall expressly include ANGIOTECHKNOWLEDGY® and CELLPAKER®.

Licensee Trademark(s) means a Trademark(s) owned or Controlled by Licensee. Licensee shall select one or more Licensee Trademarks for use in conjunction with CoStasis Product(s) (other than Licensor-Branded CoStasis Product(s)), and these Licensee Trademark(s) shall be different from Licensor Trademark(s) used in conjunction with Licensor-Branded CoStasis Product(s).

CoStasis Ingredient Improvementis defined as  With respect to an Improvement to the CoStasis Ingredients and/or the Formulated CoStasis Ingredients (including, without limitation, any Improvement constituting a composition, method of making and/or method of using any of the foregoing) that is conceived, reduced to practice, discovered, derived or developed by or on behalf of Licensee or its Affiliates (each, a CoStasis Ingredient Improvement), Licensee and its Affiliates agree to assign, and hereby do assign, their right, title and interest in and to each such CoStasis Ingredient Improvement to Licensor.

CoStasis Ingredient Improvement Patents is defined as  Licensor shall file, prosecute and maintain in force (a) any and all patents and patent applications included in the Licensed Patents, (b) any and all patent and patent applications related to any CoStasis Ingredient Improvement.

Field of Use
Licensed Field means, collectively or individually, as the context requires, (a) the Orthopedic Hemostat Field; (b) the Non-Orthopedic Hemostat Field; and (c) the CellPaker Field. The terms “Licensed Field,” “Orthopedic Hemostat Field” and “Non-Orthopedic Hemostat Field” are expressly inapplicable to Drug-Loaded Products, even if a Drug-Loaded Product is approved for human use in the Licensed Field.

Orthopedic Hemostat Field means, with respect to a CoStasis Product, human medical uses of the CoStasis Product as a Hemostat for all indications treated by an orthopedic surgeon or other surgeon relating to the surgical repair of diseases or injuries of the spine, bone or related soft tissue, such as ligaments or cartilage.

Non-Orthopedic Hemostat Field means, with respect to a CoStasis Product, human medical uses of the CoStasis Product as a Hemostat for all indications, other than indications within the Orthopedic Hemostat Field.

Hemostat means a product, the primary purpose of which is to stop bleeding through an activation of the coagulation cascade.

CellPaker Field means human medical uses of the CellPaker Products and/or Accessories in connection with CoStasis Products.

IPSCIO Record ID: 369243

License Grant
For the CoSeal Sealant Units Exclusive Distribution, Sales and Marketing Rights,  Licensors of the United States, Switzerland and Canada grant
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in the Sealant Territory; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in the Sealant Territory during the term of this Distribution and License Agreement.

For the CoSeal Sealant Option, Licensor grants an option (the CoSeal Sealant Option)
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in Japan; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Sealant Units in Japan.

For the CoSeal Adhesion Prevention Units Exclusive Distribution, Sales and Marketing Rights, Licensor grants
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the Adhesion Prevention Territory; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the Adhesion Prevention Territory during the term of this Distribution and License Agreement.

For the CoSeal Adhesion Prevention Option, Licensor grants to an option (the CoSeal Adhesion Prevention Option)
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the United States; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Adhesion Prevention Units in the United States.

For the CoSeal Accessories Exclusive Rights, Licensor grants
— a sole and exclusive license, with right to sublicense, under Licensor Patents and Trademarks to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import CoSeal Accessories in the Field in the Territory; and
— a non-exclusive license, with right to sublicense, under Licensor Know-How to use, have used, market, have marketed, distribute, have distributed, sell, have sold, offer for sale, export and import the CoSeal Accessories in the Field in the Territory.

License Property
The trademarks include COSEAL©, ADHIBIT™, and, ANGIOTECHKNOWLEDGY™.

CoSeal Ingredients shall mean the two derivatized polyethylene glycol ingredients, designated COH102 and COH206

CoSeal Adhesion Prevention Unit shall mean a CoSeal Adhesion Prevention Product sold in combination with a CoSeal Adhesion Prevention Device.

CoSeal Devices shall mean, collectively, as the context requires, both or either of the CoSeal Adhesion Prevention Devices and/or the CoSeal Sealant Devices.

CoSeal Unit shall mean, collectively, as the context requires, both or either of the CoSeal Sealant Unit and/or the CoSeal Adhesion Prevention Unit.

CoSeal Sealant Unit shall mean a CoSeal Sealant Product sold in combination with a CoSeal Sealant Device.

CoSeal Sealant Product shall mean a product containing the CoSeal Ingredients that is the subject matter of a Regulatory Filing for use as a tissue sealant, adhesive or glue, has been or is approved by one or more Regulatory Authorities for use as a tissue sealant, adhesive or glue, or that is in development or sold for use as a tissue sealant, adhesive or glue.

Field of Use
CoSeal is indicated for use in vascular reconstructions to achieve adjunctive ·hemostasis by mechanically sealing areas of leakage.  CoSeal is designed to rapidly seal tissue surfaces, suture lines and synthetic grafts during surgery.

Field shall mean human therapeutic use for any and all tissue sealing, adhesive, glue or adhesion prevention barrier indications but shall specifically exclude any use (i) in Hemostat indications; (ii) for tissue regeneration indications; (iii) as an osteobiologic for skeletal repair an non-pharmacologic devices for osteoarthritis treatment,; (iv) as a urinary incontinence product and for the treatment of urinary incontinence; or (v) as an ostomy product.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.